Spinal Muscular Atrophy Market is Touching New Levels – To Grow at a Healthy CAGR by 2027 with Key players

The Global Spinal Muscular Atrophy (SMA) Market, by Disease Type (Type I, Type II, Type III, Type IV) Treatment (Gene Therapy and Drugs), by Age (Infant and Adult),and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was estimated to be valued at US$ 884 million in 2017 and is projected to exhibit a CAGR of 12.4% over the forecast period (2018 – 2026). Spinal muscular atrophy market is expected to grow at significant rate, owing to rising number of clinical trials being conducted to develop effective treatment for the disease.

Get Sample Here

Increasing focus on clinical trials is expected to drive growth of the spinal muscular atrophy (SMA) market

The spinal muscular atrophy market is predicted to develop due to an increase in the number of clinical trials being done by leading industry players and increased government backing for these clinical trials. Since motor neurons control muscular action in the body, various clinical research are focusing on therapeutic techniques to boost survival motor neuron (SMN) protein in motor neurons. SMN protein is important for maintenance of motor neurons, which are located in the spinal cord and brainstem, the part of the brain that is connected to the spinal cord.

Spinraza is the only approved medication therapy for spinal muscular atrophy currently available. The FDA authorised Biogen’s Spinraza (nusinersen) medication for the treatment of SMA in 2016. Spinraza works by addressing the underlying cause of SMA, allowing it to help avoid, delay, or even reverse symptoms. It does, however, have a higher risk of constipation and respiratory tract infection, as well as a lower risk of kidney issues and bleeding. Several biotechnology and biopharmaceutical behemoths are collaborating to create a viable SMA therapy. For example, AveXis gained FDA permission to manufacture AVXS-101 gene therapy in 2017. It is currently in the development stage and was granted Orphan Drug Designation and Breakthrough Therapy Designation in 2017 for the treatment of all kinds of spinal muscular atrophy (SMA).It also received Fast Track Designation in 2016, for the treatment of SMA Type 1—one of the most chronic neurological genetic disorders.

In April 2018, AveXis announced launching of a Phase 3 trial, for STR1VE in infants with SMA type 1. AveXis also plans to initiate a similar trial in Europe called STR1VE EU.

To increase their market share, key firms are working on mergers and acquisitions, new product launches, and collaborations. For example, in 2016, Ionis discovered Spinraza and collaborated with Biogen to develop the medicine. Biogen paid Ionis a total of US$ 320 million for the development of Spinraza through 2016, including US$ 90 million in regulatory approvals in Japan and Europe. Roche, another important player, bought Trophos in 2015 with the goal of continuing Olesoxime clinical trials. The business is actively recruiting people with SMA type II or III for a Phase 3 research.
Key Takeaways of the Spinal Muscular Atrophy Market:
• Due to an increase in the number of clinical studies for the discovery of novel medicines, the worldwide spinal muscular atrophy market is predicted to grow at a CAGR of 12.4% over the forecast period.
• Due to the approval of the single medicine Spinraza, the pharmaceuticals segment is expected to keep the dominating position in the spinal muscular atrophy market in 2017.
• In 2017, the type I segment of the spinal muscular atrophy market is expected to be the most prominent among disease types. This is due to the fact that it is the most prevalent and severe type of SMA. Type I accounts for 50 percent to 70 percent of instances of childhood-onset SMA, according to SMA Europe 2015 data. North America dominated the market in 2017, owing to a larger demand for spinal muscular atrophy treatment as a result of the region’s higher diagnostic rate.
Biogen, Cytokinetics, Inc., F. Hoffmann-La Roche, Novartis AG, Pfizer, and Ionis Pharmaceuticals, Inc. are among the major participants in the worldwide spinal muscular atrophy market.

Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1920

Spinal Muscular Atrophy Market – Competitive Landscape

Key players functioning in the global prosthetic liners market consists of Biogen, Cytokinetics, Inc., F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., and Ionis Pharmaceuticals, Inc.

Main points in Spinal Muscular Atrophy Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Spinal Muscular Atrophy Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Spinal Muscular Atrophy Industry Impact

Chapter 2 Global Spinal Muscular Atrophy Competition by Types, Applications, and Top Regions and Countries
2.1 Global Spinal Muscular Atrophy (Volume and Value) by Type
2.3 Global Spinal Muscular Atrophy (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Spinal Muscular Atrophy Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Spinal Muscular Atrophy Market Analysis
Chapter 6 East Asia Spinal Muscular Atrophy Market Analysis
Chapter 7 Europe Spinal Muscular Atrophy Market Analysis
Chapter 8 South Asia Spinal Muscular Atrophy Market Analysis
Chapter 9 Southeast Asia Spinal Muscular Atrophy Market Analysis
Chapter 10 Middle East Spinal Muscular Atrophy Market Analysis
Chapter 11 Africa Spinal Muscular Atrophy Market Analysis
Chapter 12 Oceania Spinal Muscular Atrophy Market Analysis
Chapter 13 South America Spinal Muscular Atrophy Market Analysis
Chapter 14 Company Profiles and Key Figures in Spinal Muscular Atrophy Business
Chapter 15 Global Spinal Muscular Atrophy Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com